|
G
|
Ager
|
advanced glycosylation end product-specific receptor
|
multiple interactions
|
ISO
|
[Tobacco Smoke Pollution results in increased abundance of Cotinine] which affects the methylation of AGER gene
|
CTD |
PMID:34009014 |
|
NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685
|
|
G
|
Ahrr
|
aryl-hydrocarbon receptor repressor
|
affects methylation
|
ISO
|
Cotinine affects the methylation of AHRR gene
|
CTD |
PMID:22851337 |
|
NCBI chr 1:30,822,219...30,917,251
Ensembl chr 1:30,810,866...30,952,866
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
increases phosphorylation multiple interactions
|
ISO
|
Cotinine results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cotinine results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:22687995 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Bsg
|
basigin
|
multiple interactions
|
ISO
|
[Tobacco Smoke Pollution results in increased abundance of Cotinine] which affects the methylation of BSG gene
|
CTD |
PMID:34009014 |
|
NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:10,643,789...10,651,005
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
Cotinine inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]
|
CTD |
PMID:22687995 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp7
|
caspase 7
|
multiple interactions
|
ISO
|
Cotinine inhibits the reaction [Doxorubicin results in increased activity of CASP7 protein]
|
CTD |
PMID:22687995 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
G
|
Ccnd1
|
cyclin D1
|
increases expression
|
ISO
|
Cotinine results in increased expression of CCND1 protein
|
CTD |
PMID:31678612 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cd68
|
Cd68 molecule
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of CD68 mRNA
|
CTD |
PMID:29617909 |
|
NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540
|
|
G
|
Cebpa
|
CCAAT/enhancer binding protein alpha
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of CEBPA protein
|
CTD |
PMID:29617909 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of CEBPB mRNA
|
CTD |
PMID:29617909 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
G
|
Chrna7
|
cholinergic receptor nicotinic alpha 7 subunit
|
increases response to substance multiple interactions
|
ISO
|
CHRNA7 protein mutant form results in increased susceptibility to Cotinine Cotinine binds to and results in increased activity of CHRNA7 protein
|
CTD |
PMID:10082212 |
|
NCBI chr 1:126,123,425...126,249,181
Ensembl chr 1:126,123,425...126,446,858
|
|
G
|
Cntnap2
|
contactin associated protein 2
|
affects methylation
|
ISO
|
Cotinine affects the methylation of CNTNAP2 gene
|
CTD |
PMID:22851337 |
|
NCBI chr 4:75,109,358...77,366,258
Ensembl chr 4:75,109,858...77,366,258
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
affects methylation
|
ISO
|
Cotinine affects the methylation of CYP1A1 gene
|
CTD |
PMID:22851337 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases activity decreases activity
|
ISO
|
Cotinine results in increased activity of CYP1A2 protein Cotinine results in decreased activity of CYP1A2 protein
|
CTD |
PMID:15916432 PMID:16203240 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
increases abundance multiple interactions
|
EXP
|
CYP2B1 protein results in increased abundance of Cotinine [Nicotine results in increased expression of CYP2B1 protein] which results in increased abundance of Cotinine
|
CTD |
PMID:10799646 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
increases chemical synthesis
|
ISO
|
CYP2B6 protein results in increased chemical synthesis of Cotinine
|
CTD |
PMID:12488541 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Dcx
|
doublecortin
|
multiple interactions
|
ISO
|
[diethyl phosphate co-treated with Cotinine co-treated with bis(2,3,3,3-tetrachloropropyl) ether co-treated with Mercury co-treated with Selenium] results in increased expression of DCX mRNA
|
CTD |
PMID:37914285 |
|
NCBI chr X:112,227,455...112,370,291
Ensembl chr X:112,227,455...112,304,161
|
|
G
|
Dlgap2
|
DLG associated protein 2
|
multiple interactions
|
ISO
|
[Tobacco Smoke Pollution results in increased abundance of Cotinine] which affects the methylation of DLGAP2 gene
|
CTD |
PMID:34009014 |
|
NCBI chr16:81,489,059...82,198,693
Ensembl chr16:81,494,649...82,198,684
|
|
G
|
Ext1
|
exostosin glycosyltransferase 1
|
affects methylation
|
ISO
|
Cotinine affects the methylation of EXT1 gene
|
CTD |
PMID:22851337 |
|
NCBI chr 7:86,265,651...86,544,488
Ensembl chr 7:86,259,900...86,544,567
|
|
G
|
Fhit
|
fragile histidine triad diadenosine triphosphatase
|
multiple interactions
|
ISO
|
[Tobacco Smoke Pollution results in increased abundance of Cotinine] which affects the methylation of FHIT gene
|
CTD |
PMID:34009014 |
|
NCBI chr15:16,365,401...17,872,901
Ensembl chr15:16,747,338...17,872,621
|
|
G
|
Gfi1
|
growth factor independent 1 transcriptional repressor
|
affects methylation
|
ISO
|
Cotinine affects the methylation of GFI1 gene
|
CTD |
PMID:22851337 |
|
NCBI chr14:2,185,489...2,204,191
Ensembl chr14:2,187,286...2,196,730
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of IL1B mRNA
|
CTD |
PMID:29617909 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of IL6 mRNA
|
CTD |
PMID:29617909 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Map2
|
microtubule-associated protein 2
|
multiple interactions
|
ISO
|
[diethyl phosphate co-treated with Cotinine co-treated with bis(2,3,3,3-tetrachloropropyl) ether co-treated with Mercury co-treated with Selenium] results in increased expression of MAP2 mRNA
|
CTD |
PMID:37914285 |
|
NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
decreases phosphorylation
|
ISO
|
Cotinine results in decreased phosphorylation of MAPK1 protein
|
CTD |
PMID:31678612 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
decreases phosphorylation
|
ISO
|
Cotinine results in decreased phosphorylation of MAPK3 protein
|
CTD |
PMID:31678612 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
increases expression
|
EXP
|
Cotinine results in increased expression of MKI67 protein
|
CTD |
PMID:31678612 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
G
|
Myo1g
|
myosin IG
|
affects methylation
|
ISO
|
Cotinine affects the methylation of MYO1G gene
|
CTD |
PMID:22851337 |
|
NCBI chr14:85,600,619...85,615,760
Ensembl chr14:85,600,619...85,615,760
|
|
G
|
Nat1
|
N-acetyltransferase 1
|
multiple interactions affects abundance
|
ISO
|
[NAT1 gene SNP affects the susceptibility to Tobacco Smoke Pollution] which results in increased abundance of Cotinine; NAT1 gene polymorphism affects the reaction [Tobacco Smoke Pollution results in increased abundance of Cotinine] NAT1 gene polymorphism affects the abundance of Cotinine
|
CTD |
PMID:25156213 PMID:31809667 |
|
NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527
|
|
G
|
Pax6
|
paired box 6
|
multiple interactions
|
ISO
|
[diethyl phosphate co-treated with Cotinine co-treated with bis(2,3,3,3-tetrachloropropyl) ether co-treated with Mercury co-treated with Selenium] results in increased expression of PAX6 mRNA
|
CTD |
PMID:37914285 |
|
NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763
|
|
G
|
Pnpla2
|
patatin-like phospholipase domain containing 2
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 mRNA; [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 protein
|
CTD |
PMID:29617909 |
|
NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359
|
|
G
|
Prkg1
|
protein kinase cGMP-dependent 1
|
multiple interactions
|
ISO
|
[Tobacco Smoke Pollution results in increased abundance of Cotinine] which affects the methylation of PRKG1 gene
|
CTD |
PMID:34009014 |
|
NCBI chr 1:237,818,950...239,052,184
Ensembl chr 1:237,823,053...239,103,005
|
|
G
|
Rbfox3
|
RNA binding fox-1 homolog 3
|
multiple interactions
|
ISO
|
[diethyl phosphate co-treated with Cotinine co-treated with bis(2,3,3,3-tetrachloropropyl) ether co-treated with Mercury co-treated with Selenium] results in increased expression of RBFOX3 mRNA
|
CTD |
PMID:37914285 |
|
NCBI chr10:104,218,940...104,655,863
Ensembl chr10:104,218,940...104,551,945
|
|
G
|
Runx1
|
RUNX family transcription factor 1
|
affects methylation
|
ISO
|
Cotinine affects the methylation of RUNX1 gene
|
CTD |
PMID:22851337 |
|
NCBI chr11:45,325,778...45,560,300
Ensembl chr11:45,329,044...45,564,925
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD1 mRNA; [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD1 protein
|
CTD |
PMID:29617909 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD2 protein
|
CTD |
PMID:29617909 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of SREBF1 mRNA
|
CTD |
PMID:29617909 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
increases phosphorylation
|
ISO
|
Cotinine results in increased phosphorylation of STAT3 protein
|
CTD |
PMID:31678612 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
EXP
|
[Nicotine results in increased abundance of Cotinine] which results in increased expression of TNF mRNA
|
CTD |
PMID:29617909 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Ttc7b
|
tetratricopeptide repeat domain 7B
|
affects methylation
|
ISO
|
Cotinine affects the methylation of TTC7B gene
|
CTD |
PMID:22851337 |
|
NCBI chr 6:125,317,011...125,528,843
Ensembl chr 6:125,316,789...125,528,779
|
|
G
|
Ugt1a5
|
UDP glucuronosyltransferase family 1 member A5
|
increases glucuronidation
|
ISO
|
UGT1A4 protein results in increased glucuronidation of Cotinine
|
CTD |
PMID:14570768 PMID:16141602 |
|
NCBI chr 9:96,210,053...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a9
|
UDP glucuronosyltransferase family 1 member A9
|
increases glucuronidation
|
ISO
|
UGT1A9 protein results in increased glucuronidation of Cotinine
|
CTD |
PMID:16141602 |
|
NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
|
G
|
Dek
|
DEK proto-oncogene
|
multiple interactions
|
ISO
|
DEK protein results in decreased chemical synthesis of and results in increased uptake of Pyrrolidonecarboxylic Acid
|
CTD |
PMID:28558019 |
|
NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,787,139...17,810,122
|
|
G
|
Ins2
|
insulin 2
|
multiple interactions
|
ISO
|
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Pyrrolidonecarboxylic Acid analog
|
CTD |
PMID:26820058 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions
|
ISO
|
[NR1I2 protein affects the susceptibility to Pregnenolone Carbonitrile] which affects the abundance of Pyrrolidonecarboxylic Acid
|
CTD |
PMID:38971454 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
EXP
|
[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased phosphorylation of AKT1 protein
|
CTD |
PMID:15287886 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
multiple interactions
|
EXP
|
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline inhibits the reaction [[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased expression of BDNF mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased expression of BDNF mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased secretion of BDNF protein]; [alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased expression of BDNF mRNA; [alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased secretion of BDNF protein; U 0126 inhibits the reaction [[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased expression of BDNF mRNA]
|
CTD |
PMID:15287886 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Ces1d
|
carboxylesterase 1D
|
increases hydrolysis
|
ISO
|
CES1 protein results in increased hydrolysis of aniracetam
|
CTD |
PMID:9300133 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449
|
|
G
|
Ces2h
|
carboxylesterase 2H
|
increases hydrolysis
|
ISO
|
CES2 protein results in increased hydrolysis of aniracetam
|
CTD |
PMID:9300133 |
|
NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752
|
|
G
|
Lyn
|
LYN proto-oncogene, Src family tyrosine kinase
|
multiple interactions
|
EXP
|
[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased phosphorylation of LYN protein
|
CTD |
PMID:15287886 |
|
NCBI chr 5:21,437,127...21,553,097
Ensembl chr 5:21,437,084...21,554,461
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased phosphorylation of MAPK1 protein]; [alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased phosphorylation of MAPK1 protein; Wortmannin inhibits the reaction [[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:15287886 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased phosphorylation of MAPK3 protein]; [alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased phosphorylation of MAPK3 protein; Wortmannin inhibits the reaction [[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:15287886 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Ntrk2
|
neurotrophic receptor tyrosine kinase 2
|
multiple interactions
|
EXP
|
[alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid co-treated with aniracetam] results in increased phosphorylation of NTRK2 protein
|
CTD |
PMID:15287886 |
|
NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,564,570...5,874,628
|
|
|
G
|
Crh
|
corticotropin releasing hormone
|
increases expression
|
EXP
|
Doxapram results in increased expression of CRH mRNA; Doxapram results in increased expression of CRH protein
|
CTD |
PMID:16269353 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386
|
|
G
|
Prl
|
prolactin
|
increases expression
|
ISO
|
Doxapram results in increased expression of PRL protein
|
CTD |
PMID:15741000 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions increases expression increases transport decreases activity
|
EXP ISO
|
Amino Acids, Peptides, and Proteins inhibits the reaction [Levetiracetam results in increased expression of ABCB1 protein] ABCB1A protein results in increased transport of Levetiracetam Levetiracetam results in decreased activity of ABCB1 protein
|
CTD |
PMID:17045309 PMID:18408562 PMID:18473823 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of ABCC1 protein
|
CTD |
PMID:18473823 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of ABCC2 protein
|
CTD |
PMID:18473823 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Acvrl1
|
activin A receptor like type 1
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of ACVRL1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 7:134,117,917...134,135,306
Ensembl chr 7:134,118,024...134,135,305
|
|
G
|
Amy1
|
amylase alpha 1
|
decreases activity
|
EXP
|
Levetiracetam results in decreased activity of AMY1 protein
|
CTD |
PMID:37572749 |
|
NCBI chr 2:204,071,101...204,085,910
Ensembl chr 2:204,071,098...204,086,239
|
|
G
|
Arhgef1
|
Rho guanine nucleotide exchange factor 1
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of ARHGEF1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 1:89,626,884...89,648,823
Ensembl chr 1:89,628,266...89,649,067
|
|
G
|
Atg7
|
autophagy related 7
|
decreases expression multiple interactions
|
EXP
|
Levetiracetam results in decreased expression of ATG7 protein Quercetin inhibits the reaction [Levetiracetam results in decreased expression of ATG7 protein]
|
CTD |
PMID:37098359 |
|
NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
EXP
|
Levetiracetam results in decreased expression of BCL2 protein Quercetin inhibits the reaction [Levetiracetam results in decreased expression of BCL2 protein]
|
CTD |
PMID:37098359 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Cacnb1
|
calcium voltage-gated channel auxiliary subunit beta 1
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of CACNB1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr10:83,494,509...83,515,164
Ensembl chr10:83,494,509...83,515,146
|
|
G
|
Casp3
|
caspase 3
|
increases activity multiple interactions
|
EXP
|
Levetiracetam results in increased activity of CASP3 protein Quercetin inhibits the reaction [Levetiracetam results in increased activity of CASP3 protein]
|
CTD |
PMID:37098359 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cat
|
catalase
|
multiple interactions decreases expression
|
ISO EXP
|
Levetiracetam inhibits the reaction [Pilocarpine results in increased activity of CAT protein] Quercetin inhibits the reaction [Levetiracetam results in decreased expression of CAT protein]
|
CTD |
PMID:17205390 PMID:37098359 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccnh
|
cyclin H
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of CCNH mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 2:17,570,449...17,591,078
Ensembl chr 2:17,570,263...17,614,860
|
|
G
|
Chrm2
|
cholinergic receptor, muscarinic 2
|
increases activity decreases expression
|
ISO
|
Levetiracetam results in increased activity of CHRM2 protein Levetiracetam results in decreased expression of CHRM2 protein
|
CTD |
PMID:15967574 |
|
NCBI chr 4:65,981,136...66,116,128
Ensembl chr 4:65,981,006...66,126,464
|
|
G
|
Cxcr3
|
C-X-C motif chemokine receptor 3
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of CXCR3 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr X:70,884,293...70,886,944
Ensembl chr X:70,883,958...70,886,871
|
|
G
|
Cycs
|
cytochrome c, somatic
|
increases expression multiple interactions
|
EXP
|
Levetiracetam results in increased expression of CYCS protein Quercetin inhibits the reaction [Levetiracetam results in increased expression of CYCS protein]
|
CTD |
PMID:37098359 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Cyp17a1
|
cytochrome P450, family 17, subfamily a, polypeptide 1
|
decreases expression
|
ISO
|
Levetiracetam results in decreased expression of CYP17A1 mRNA
|
CTD |
PMID:19566492 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974
|
|
G
|
Cyp19a1
|
cytochrome P450, family 19, subfamily a, polypeptide 1
|
decreases expression
|
ISO
|
Levetiracetam results in decreased expression of CYP19A1 mRNA
|
CTD |
PMID:19566492 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917
|
|
G
|
Dao
|
D-amino-acid oxidase
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of DAO mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr12:48,252,900...48,275,964
Ensembl chr12:48,252,902...48,273,300
|
|
G
|
Dbp
|
D-box binding PAR bZIP transcription factor
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of DBP mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 1:105,312,256...105,317,205
Ensembl chr 1:105,312,108...105,317,205
|
|
G
|
Des
|
desmin
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of DES mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
multiple interactions increases expression
|
EXP
|
Quercetin inhibits the reaction [Levetiracetam results in increased expression of GJA1 protein]
|
CTD |
PMID:37098359 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
G
|
Gle1
|
GLE1 RNA export mediator
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of GLE1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 3:33,607,160...33,638,879
|
|
G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
increases activity
|
EXP
|
Levetiracetam results in increased activity of GOT1 protein
|
CTD |
PMID:37572749 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
increases activity
|
EXP
|
Levetiracetam results in increased activity of GPT protein
|
CTD |
PMID:37572749 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
decreases activity decreases expression multiple interactions
|
EXP
|
Levetiracetam results in decreased activity of GPX1 protein Levetiracetam results in decreased expression of GPX1 protein Quercetin inhibits the reaction [Levetiracetam results in decreased expression of GPX1 protein]
|
CTD |
PMID:37098359 PMID:37572749 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
G
|
Hcn2
|
hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of HCN2 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 7:10,620,422...10,639,457
Ensembl chr 7:10,620,422...10,639,457
|
|
G
|
Hdac10
|
histone deacetylase 10
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of HDAC10 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 7:122,078,768...122,084,457
Ensembl chr 7:122,078,768...122,083,870
|
|
G
|
Hmox1
|
heme oxygenase 1
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of HMOX1 protein
|
CTD |
PMID:37098359 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hmox2
|
heme oxygenase 2
|
multiple interactions
|
EXP
|
Quercetin inhibits the reaction [Levetiracetam results in decreased expression of HMOX2 protein]
|
CTD |
PMID:37098359 |
|
NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800
|
|
G
|
Hsd3b2
|
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2
|
decreases expression
|
ISO
|
Levetiracetam results in decreased expression of HSD3B2 mRNA
|
CTD |
PMID:19566492 |
|
NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases activity
|
EXP
|
Quercetin inhibits the reaction [Levetiracetam results in increased activity of IL1B protein]
|
CTD |
PMID:37098359 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Kcna4
|
potassium voltage-gated channel subfamily A member 4
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of KCNA4 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 3:114,211,091...114,218,545
Ensembl chr 3:114,210,998...114,344,932
|
|
G
|
Kctd3
|
potassium channel tetramerization domain containing 3
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of KCTD3 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr13:103,041,488...103,080,069
Ensembl chr13:103,041,490...103,080,009
|
|
G
|
Khdrbs2
|
KH RNA binding domain containing, signal transduction associated 2
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of KHDRBS2 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 9:41,943,029...42,449,687
Ensembl chr 9:41,943,050...42,412,905
|
|
G
|
Lap3
|
leucine aminopeptidase 3
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of LAP3 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr14:69,820,907...69,839,891
Ensembl chr14:69,820,908...69,839,891
|
|
G
|
Lsm1
|
LSM1 homolog, mRNA degradation associated
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of LSM1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr16:72,980,075...72,991,581
Ensembl chr16:72,979,686...73,022,396
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions decreases expression
|
EXP
|
Quercetin inhibits the reaction [Levetiracetam results in decreased expression of MTOR protein]
|
CTD |
PMID:37098359 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Nap1l2
|
nucleosome assembly protein 1-like 2
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of NAP1L2 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr X:72,239,849...72,242,247
Ensembl chr X:72,238,310...72,242,464
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions decreases expression
|
EXP
|
Quercetin inhibits the reaction [Levetiracetam results in decreased expression of NFE2L2 protein]
|
CTD |
PMID:37098359 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Ngly1
|
N-glycanase 1
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of NGLY1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr15:11,584,475...11,640,977
Ensembl chr15:11,584,475...11,635,328
|
|
G
|
Nox1
|
NADPH oxidase 1
|
multiple interactions decreases expression
|
EXP
|
Quercetin inhibits the reaction [Levetiracetam results in decreased expression of NOX1 protein]
|
CTD |
PMID:37098359 |
|
NCBI chr X:101,572,338...101,625,571
Ensembl chr X:101,572,340...101,595,520
|
|
G
|
Phldb1
|
pleckstrin homology-like domain, family B, member 1
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of PHLDB1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 8:53,900,338...53,948,325
Ensembl chr 8:53,900,338...53,949,518
|
|
G
|
Pon1
|
paraoxonase 1
|
affects activity
|
ISO
|
Levetiracetam affects the activity of PON1 protein
|
CTD |
PMID:28032682 |
|
NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924
|
|
G
|
Prkx
|
protein kinase cAMP-dependent X-linked catalytic subunit
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of PRKX mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr X:45,701,747...45,745,210
Ensembl chr X:45,701,747...45,745,066
|
|
G
|
Psip1
|
PC4 and SRSF1 interacting protein 1
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of PSIP1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 5:102,892,929...102,925,191
Ensembl chr 5:102,892,932...102,925,170
|
|
G
|
Serinc1
|
serine incorporator 1
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of SERINC1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr20:37,396,497...37,415,433
Ensembl chr20:37,396,497...37,443,124
|
|
G
|
Slc23a2
|
solute carrier family 23 member 2
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of SLC23A2 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 3:139,755,583...139,913,304
Ensembl chr 3:139,755,584...139,847,343
|
|
G
|
Slc4a7
|
solute carrier family 4 member 7
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of SLC4A7 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr15:13,015,854...13,095,485
Ensembl chr15:13,015,854...13,095,292
|
|
G
|
Smc2
|
structural maintenance of chromosomes 2
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of SMC2 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 5:71,592,428...71,648,636
Ensembl chr 5:71,602,308...71,648,632
|
|
G
|
Sod1
|
superoxide dismutase 1
|
decreases activity multiple interactions decreases expression
|
EXP
|
Levetiracetam results in decreased activity of SOD1 protein Quercetin inhibits the reaction [Levetiracetam results in decreased expression of SOD1 protein]
|
CTD |
PMID:37098359 PMID:37572749 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Star
|
steroidogenic acute regulatory protein
|
decreases expression
|
ISO
|
Levetiracetam results in decreased expression of STAR mRNA
|
CTD |
PMID:19566492 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447
|
|
G
|
Tent2
|
terminal nucleotidyltransferase 2
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of TENT2 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 2:26,115,150...26,167,465
Ensembl chr 2:26,115,240...26,167,113
|
|
G
|
Tmt1b
|
thiol methyltransferase 1B
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of TMT1B mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 7:1,973,334...1,975,980
Ensembl chr 7:1,973,337...1,975,980
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases activity multiple interactions
|
EXP
|
Levetiracetam results in increased activity of TNF protein Quercetin inhibits the reaction [Levetiracetam results in increased activity of TNF protein]
|
CTD |
PMID:37098359 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
increases activity multiple interactions
|
EXP
|
Levetiracetam results in increased activity of TP53 protein Quercetin inhibits the reaction [Levetiracetam results in increased activity of TP53 protein]
|
CTD |
PMID:37098359 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Trdmt1
|
tRNA aspartic acid methyltransferase 1
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of TRDMT1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr17:81,510,740...81,554,036
Ensembl chr17:81,521,200...81,577,639
|
|
G
|
Vars2
|
valyl-tRNA synthetase 2, mitochondrial
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of VARS2 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr20:3,081,869...3,092,907
Ensembl chr20:3,081,893...3,092,901
|
|
G
|
Xrcc1
|
X-ray repair cross complementing 1
|
decreases expression
|
EXP
|
Levetiracetam results in decreased expression of XRCC1 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613
|
|
G
|
Zfp266
|
zinc finger protein 266
|
increases expression
|
EXP
|
Levetiracetam results in increased expression of ZFP266 mRNA
|
CTD |
PMID:20345932 |
|
NCBI chr 8:27,307,015...27,338,624
Ensembl chr 8:27,307,015...27,320,143
|
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of ABCC2 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of ABCC3 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of AKT1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Akt2
|
AKT serine/threonine kinase 2
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of AKT2 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:92,014,859...92,061,420
|
|
G
|
Bcar1
|
BCAR1 scaffold protein, Cas family member
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of BCAR1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr19:56,588,500...56,623,190
Ensembl chr19:56,588,500...56,623,190
|
|
G
|
Capn1
|
calpain 1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CAPN1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 1:212,705,219...212,736,134
Ensembl chr 1:212,705,222...212,729,445
|
|
G
|
Crk
|
CRK proto-oncogene, adaptor protein
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CRK mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr10:61,028,736...61,054,971
Ensembl chr10:61,028,757...61,082,988
|
|
G
|
Csnk1d
|
casein kinase 1, delta
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK1D mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr10:106,713,497...106,754,953
Ensembl chr10:106,694,279...106,754,953
|
|
G
|
Csnk1e
|
casein kinase 1, epsilon
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK1E mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 7:112,863,726...112,887,338
Ensembl chr 7:112,863,731...112,884,101
|
|
G
|
Csnk2a1
|
casein kinase 2 alpha 1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK2A1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698
|
|
G
|
Csnk2a2
|
casein kinase 2 alpha 2
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK2A2 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr19:9,562,340...9,602,136
Ensembl chr19:9,562,321...9,602,136
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CYP2B1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp3a23-3a1
|
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CYP3A23-3A1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CYP3A9 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Ddr1
|
discoidin domain receptor tyrosine kinase 1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of DDR1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr20:3,047,269...3,069,277
Ensembl chr20:3,050,375...3,069,276
|
|
G
|
Foxg1
|
forkhead box G1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of FOXG1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 6:72,401,582...72,404,392
Ensembl chr 6:72,394,239...72,427,392
|
|
G
|
Hdac1
|
histone deacetylase 1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which affects the expression of HDAC1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387
|
|
G
|
Ilk
|
integrin-linked kinase
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of ILK mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 1:169,500,716...169,506,972
Ensembl chr 1:169,498,681...169,506,964
|
|
G
|
Lef1
|
lymphoid enhancer binding factor 1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of LEF1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which affects the expression of MDM2 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Pik3r2
|
phosphoinositide-3-kinase regulatory subunit 2
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of PIK3R2 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr16:18,699,389...18,708,045
Ensembl chr16:18,699,448...18,709,665
|
|
G
|
Ppp2r1a
|
protein phosphatase 2 scaffold subunit A alpha
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of PPP2R1A mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 1:69,213,198...69,232,441
Ensembl chr 1:69,213,038...69,238,242
|
|
G
|
Slc5a5
|
solute carrier family 5 member 5
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which affects the expression of SLC5A5 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691
|
|
G
|
Tcf3
|
transcription factor 3
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TCF3 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 7:9,931,251...9,952,994
Ensembl chr 7:9,928,685...9,953,044
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TGFB1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tgfbr2
|
transforming growth factor, beta receptor 2
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TGFBR2 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469
|
|
G
|
Tpo
|
thyroid peroxidase
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TPO mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 6:52,425,998...52,495,793
Ensembl chr 6:52,426,010...52,495,793
|
|
G
|
Tshb
|
thyroid stimulating hormone subunit beta
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TSHB protein
|
CTD |
PMID:22037397 |
|
NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:192,913,171...192,942,984
|
|
G
|
Ugt2b1
|
UDP glucuronosyltransferase 2 family, polypeptide B1
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of UGT2B1 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331
|
|
G
|
Wnt4
|
Wnt family member 4
|
multiple interactions
|
EXP
|
[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of WNT4 mRNA
|
CTD |
PMID:22037397 |
|
NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:154,797,311...154,817,128
|
|
|
G
|
Adcyap1
|
adenylate cyclase activating polypeptide 1
|
multiple interactions
|
ISO
|
Rolipram promotes the reaction [ADCYAP1 protein affects the secretion of Acids]
|
CTD |
PMID:20388963 |
|
NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions increases phosphorylation
|
EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; RAPGEF3 mutant form inhibits the reaction [Rolipram results in increased phosphorylation of AKT1 protein]; Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:18276108 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Ap2m1
|
adaptor related protein complex 2 subunit mu 1
|
multiple interactions
|
ISO
|
Rolipram inhibits the reaction [NTRK2 protein binds to AP2M1 protein]
|
CTD |
PMID:31631060 |
|
NCBI chr11:93,859,690...93,868,600
Ensembl chr11:93,859,690...93,868,480
|
|
G
|
Areg
|
amphiregulin
|
increases expression
|
ISO
|
Rolipram results in increased expression of AREG mRNA
|
CTD |
PMID:15284208 |
|
NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
EXP
|
Rolipram inhibits the reaction [Manganese results in increased expression of BAX protein]
|
CTD |
PMID:31161640 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
EXP
|
[Rolipram co-treated with Pentoxifylline] inhibits the reaction [Streptozocin results in increased expression of BCL2 protein]; Rolipram inhibits the reaction [Manganese results in decreased expression of BCL2 protein]
|
CTD |
PMID:31161640 PMID:37431890 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
multiple interactions increases expression
|
EXP
|
Rolipram inhibits the reaction [Manganese results in decreased expression of BDNF protein]; Rolipram promotes the reaction [Imipramine results in increased expression of BDNF mRNA] Rolipram results in increased expression of BDNF mRNA
|
CTD |
PMID:8601816 PMID:31161640 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
[Rolipram co-treated with Pentoxifylline] inhibits the reaction [Streptozocin results in increased cleavage of CASP3 protein]; Rolipram inhibits the reaction [Streptozocin results in increased cleavage of CASP3 protein]
|
CTD |
PMID:37431890 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions
|
EXP
|
Rolipram inhibits the reaction [Manganese results in increased activity of CASP8 protein]
|
CTD |
PMID:31161640 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions
|
EXP
|
Rolipram inhibits the reaction [Oxygen results in increased expression of CCL2 protein]
|
CTD |
PMID:18941502 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccl3
|
C-C motif chemokine ligand 3
|
multiple interactions
|
ISO
|
Rolipram inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Rolipram inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]
|
CTD |
PMID:9863660 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439
|
|
G
|
Cdh1
|
cadherin 1
|
multiple interactions increases expression
|
ISO
|
PDE4D protein inhibits the reaction [Rolipram results in increased expression of CDH1 protein] Rolipram results in increased expression of CDH1 mRNA; Rolipram results in increased expression of CDH1 protein
|
CTD |
PMID:37020384 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
multiple interactions
|
EXP
|
Rolipram promotes the reaction [FSHB protein results in increased expression of CEBPB protein]
|
CTD |
PMID:25253736 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
multiple interactions increases activity decreases activity
|
ISO
|
Rolipram promotes the reaction [CFTR protein affects the secretion of Chlorides] Rolipram results in increased activity of CFTR protein Rolipram results in decreased activity of CFTR protein
|
CTD |
PMID:12714375 PMID:15611099 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Creb1
|
cAMP responsive element binding protein 1
|
multiple interactions increases phosphorylation increases expression
|
EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]]; Rolipram inhibits the reaction [Manganese results in decreased phosphorylation of CREB1 protein]; Rolipram promotes the reaction [Imipramine results in increased expression of CREB1 mRNA]; Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein] Rolipram results in increased phosphorylation of CREB1 protein Rolipram results in increased expression of CREB1 mRNA
|
CTD |
PMID:8601816 PMID:10908723 PMID:18276108 PMID:31161640 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
G
|
Cxcl10
|
C-X-C motif chemokine ligand 10
|
decreases secretion
|
ISO
|
Rolipram results in decreased secretion of CXCL10 protein
|
CTD |
PMID:17996064 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261
|
|
G
|
Cyp19a1
|
cytochrome P450, family 19, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
Rolipram inhibits the reaction [Atrazine inhibits the reaction [FSHB protein results in increased expression of CYP19A1 mRNA]]
|
CTD |
PMID:28859905 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917
|
|
G
|
Edn1
|
endothelin 1
|
increases activity
|
EXP
|
Rolipram results in increased activity of EDN1 protein
|
CTD |
PMID:15464066 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Epx
|
eosinophil peroxidase
|
multiple interactions
|
EXP
|
Rolipram inhibits the reaction [sephadex results in increased expression of EPX protein]
|
CTD |
PMID:10850854 |
|
NCBI chr10:73,164,096...73,175,180
Ensembl chr10:73,164,096...73,175,180
|
|
G
|
Fshb
|
follicle stimulating hormone subunit beta
|
multiple interactions
|
EXP ISO
|
Rolipram promotes the reaction [FSHB protein results in increased expression of CEBPB protein]; Rolipram promotes the reaction [FSHB protein results in increased expression of STAR mRNA] Rolipram inhibits the reaction [Atrazine inhibits the reaction [FSHB protein results in increased expression of CYP19A1 mRNA]]; Rolipram inhibits the reaction [Atrazine inhibits the reaction [FSHB protein results in increased expression of STAR mRNA]]
|
CTD |
PMID:25253736 PMID:28859905 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072
|
|
G
|
Il10
|
interleukin 10
|
decreases secretion
|
ISO
|
Rolipram results in decreased secretion of IL10 protein
|
CTD |
PMID:9819297 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il13
|
interleukin 13
|
decreases expression decreases secretion
|
ISO
|
Rolipram results in decreased expression of IL13 mRNA Rolipram results in decreased secretion of IL13 protein
|
CTD |
PMID:16083514 |
|
NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483
|
|
G
|
Il18
|
interleukin 18
|
multiple interactions
|
ISO
|
Rolipram inhibits the reaction [Picryl Chloride results in increased expression of IL18 protein]
|
CTD |
PMID:16442096 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO EXP
|
Rolipram inhibits the reaction [Picryl Chloride results in increased expression of IL1B protein] Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP] Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]
|
CTD |
PMID:8904084 PMID:16442096 PMID:18710439 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il4
|
interleukin 4
|
multiple interactions
|
ISO
|
Rolipram inhibits the reaction [Picryl Chloride results in increased expression of IL4 protein]
|
CTD |
PMID:16442096 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
Rolipram inhibits the reaction [Picryl Chloride results in increased expression of IL6 protein] Rolipram promotes the reaction [TNF protein results in increased expression of IL6 mRNA]
|
CTD |
PMID:16442096 PMID:24771768 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Itgam
|
integrin subunit alpha M
|
multiple interactions
|
ISO
|
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]
|
CTD |
PMID:21457779 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
decreases activity
|
ISO
|
Rolipram results in decreased activity of KCNH2 protein
|
CTD |
PMID:17146843 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
G
|
Ltc4s
|
leukotriene C4 synthase
|
decreases secretion
|
ISO
|
Rolipram results in decreased secretion of LTC4S protein
|
CTD |
PMID:16083514 |
|
NCBI chr10:35,060,002...35,066,466
Ensembl chr10:35,061,437...35,063,768
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
EXP
|
[Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK1 protein; Dieldrin promotes the reaction [[Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:35137321 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
EXP
|
[Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK3 protein; Dieldrin promotes the reaction [[Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:35137321 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions decreases expression
|
ISO
|
PDE4D protein inhibits the reaction [Rolipram results in decreased expression of MMP9 protein] Rolipram results in decreased expression of MMP9 mRNA; Rolipram results in decreased expression of MMP9 protein
|
CTD |
PMID:37020384 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO EXP
|
Rolipram inhibits the reaction [Picryl Chloride results in increased activity of MPO protein] Rolipram inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Rolipram inhibits the reaction [Indomethacin results in increased activity of MPO protein]
|
CTD |
PMID:14567935 PMID:16442096 PMID:18710439 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
EXP
|
Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]
|
CTD |
PMID:18710439 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Ntrk2
|
neurotrophic receptor tyrosine kinase 2
|
increases expression multiple interactions
|
EXP ISO
|
Rolipram results in increased expression of NTRK2 mRNA Rolipram inhibits the reaction [NTRK2 protein binds to AP2M1 protein]
|
CTD |
PMID:8601816 PMID:31631060 |
|
NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,564,570...5,874,628
|
|
G
|
Pde4a
|
phosphodiesterase 4A
|
multiple interactions decreases activity
|
ISO EXP
|
[Albuterol co-treated with Rolipram] results in increased expression of PDE4A mRNA Rolipram results in decreased activity of PDE4A protein
|
CTD |
PMID:10763856 PMID:15922051 PMID:31195342 |
|
NCBI chr 8:27,966,978...28,029,721
Ensembl chr 8:27,966,996...28,046,924
|
|
G
|
Pde4b
|
phosphodiesterase 4B
|
multiple interactions decreases activity
|
ISO EXP
|
[Albuterol co-treated with Rolipram] results in increased expression of PDE4B mRNA Rolipram results in decreased activity of PDE4B protein Rolipram inhibits the reaction [Manganese results in increased expression of PDE4B protein] Rolipram inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]
|
CTD |
PMID:10763856 PMID:20384571 PMID:31161640 PMID:31195342 |
|
NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:122,135,174...122,598,267
|
|
G
|
Pde4d
|
phosphodiesterase 4D
|
decreases expression multiple interactions
|
ISO
|
Rolipram results in decreased expression of PDE4D protein PDE4D protein inhibits the reaction [Rolipram results in decreased expression of MMP9 protein]; PDE4D protein inhibits the reaction [Rolipram results in decreased expression of TIMP1 protein]; PDE4D protein inhibits the reaction [Rolipram results in decreased expression of VIM protein]; PDE4D protein inhibits the reaction [Rolipram results in increased expression of CDH1 protein]
|
CTD |
PMID:37020384 |
|
NCBI chr 2:41,748,337...43,262,567
Ensembl chr 2:42,110,838...43,262,569
|
|
G
|
Rap1a
|
RAP1A, member of RAS oncogene family
|
multiple interactions
|
EXP
|
Rolipram affects the reaction [Colforsin results in increased activity of RAP1A protein]
|
CTD |
PMID:10908723 |
|
NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:195,896,971...195,974,808
|
|
G
|
Rap1b
|
RAP1B, member of RAS oncogene family
|
multiple interactions
|
EXP
|
Rolipram affects the reaction [Colforsin results in increased activity of RAP1B protein]
|
CTD |
PMID:10908723 |
|
NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:55,308,922...55,342,217
|
|
G
|
Rapgef3
|
Rap guanine nucleotide exchange factor 3
|
multiple interactions increases expression
|
EXP
|
RAPGEF3 mutant form inhibits the reaction [Rolipram results in increased phosphorylation of AKT1 protein] Rolipram results in increased expression of RAPGEF3 protein
|
CTD |
PMID:18276108 |
|
NCBI chr 7:130,754,883...130,777,303
Ensembl chr 7:130,754,871...130,777,668
|
|
G
|
Sele
|
selectin E
|
multiple interactions
|
ISO
|
[Colforsin co-treated with Rolipram] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein]
|
CTD |
PMID:8780174 |
|
NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903
|
|
G
|
Smad1
|
SMAD family member 1
|
decreases expression
|
ISO
|
Rolipram results in decreased expression of SMAD1 protein
|
CTD |
PMID:37020384 |
|
NCBI chr19:45,417,430...45,477,962
Ensembl chr19:45,417,433...45,477,957
|
|
G
|
Smad4
|
SMAD family member 4
|
decreases expression
|
ISO
|
Rolipram results in decreased expression of SMAD4 protein
|
CTD |
PMID:37020384 |
|
NCBI chr18:69,518,988...69,549,684
Ensembl chr18:69,518,988...69,549,684
|
|
G
|
Socs3
|
suppressor of cytokine signaling 3
|
multiple interactions increases expression
|
ISO
|
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] Rolipram results in increased expression of SOCS3 protein
|
CTD |
PMID:23782265 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825
|
|
G
|
Spp1
|
secreted phosphoprotein 1
|
multiple interactions
|
EXP
|
Rolipram inhibits the reaction [Oxygen results in increased expression of SPP1 mRNA]; Rolipram inhibits the reaction [Oxygen results in increased expression of SPP1 protein]
|
CTD |
PMID:18941502 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820
|
|
G
|
Star
|
steroidogenic acute regulatory protein
|
multiple interactions
|
EXP ISO
|
Rolipram promotes the reaction [FSHB protein results in increased expression of STAR mRNA] Rolipram inhibits the reaction [Atrazine inhibits the reaction [FSHB protein results in increased expression of STAR mRNA]]
|
CTD |
PMID:25253736 PMID:28859905 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
decreases secretion
|
ISO
|
Rolipram results in decreased secretion of TGFB1 protein
|
CTD |
PMID:37020384 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
decreases expression multiple interactions
|
ISO
|
Rolipram results in decreased expression of TIMP1 mRNA; Rolipram results in decreased expression of TIMP1 protein PDE4D protein inhibits the reaction [Rolipram results in decreased expression of TIMP1 protein]
|
CTD |
PMID:37020384 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions decreases secretion decreases expression
|
ISO EXP
|
Rolipram inhibits the reaction [[Lipopolysaccharides co-treated with deoxynivalenol] results in increased expression of TNF protein] [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein]; Rolipram inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Rolipram promotes the reaction [TNF protein results in increased expression of IL6 mRNA] Rolipram results in decreased secretion of TNF protein Rolipram results in decreased expression of TNF protein Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of TNF mRNA]
|
CTD |
PMID:8780174 PMID:8937731 PMID:9819297 PMID:11922776 PMID:15231041 PMID:18710439 PMID:24771768 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Vim
|
vimentin
|
decreases expression multiple interactions
|
ISO
|
Rolipram results in decreased expression of VIM protein PDE4D protein inhibits the reaction [Rolipram results in decreased expression of VIM protein]
|
CTD |
PMID:37020384 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|